NVIDIA doubles down on AI in healthcare with drug discovery deals
Pharmaceutical Technology
MARCH 19, 2024
In addition to drug discovery deals, NVIDIA also announced partnerships with J&J MedTech and GE Healthcare for genAI in MedTech.
Tue.Mar 19, 2024
281 
Expert Reveals What Intermittent Fasting Could Be Doing to Your Brain
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 19, 2024
Intermittent fasting has become a popular dietary approach to help people lose or manage their weight. It has also been promoted as a way to reset metabolism, control chronic disease, slow ageing and improve overall health.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Biden’s administration initiative aims to advance women’s health conditions
Pharmaceutical Technology
MARCH 19, 2024
The new initiative aims to spur innovation and mobilisation of sectors to drive women’s health research.
Engrail’s precision psychiatry drugs get more buy in from venture investors
Bio Pharma Dive
MARCH 19, 2024
The San Diego-based startup added $157 million in new funding to back a drug for generalized anxiety order that’s now in human testing.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA approves Orchard’s Lenmeldy gene therapy for MLD
Pharmaceutical Technology
MARCH 19, 2024
The US FDA has granted approval to Orchard Therapeutics' Lenmeldy for specific forms of metachromatic leukodystrophy (MLD).
AstraZeneca buys into radiopharmaceuticals with $2.4B deal for Fusion Pharma
Bio Pharma Dive
MARCH 19, 2024
The deal hands AstraZeneca a prostate cancer drug that’s designed differently than Novartis’ fast-selling Pluvicto and currently in mid-stage testing.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Orchard follows buyout with FDA approval of rare disease gene therapy
Bio Pharma Dive
MARCH 19, 2024
The U.S. clearance of Lenmeldy, for a rare and inherited metabolic disease, triggers an additional payout related to Kyowa Kirin’s recent deal to acquire the once high-flying gene therapy developer.
Traceability technologies tighten supply chain fakery
Pharmaceutical Technology
MARCH 19, 2024
Rising numbers of counterfeit drugs are entering pharmaceutical supply chains, necessitating advanced track-and-trace systems.
With new data, Bayer readies rival to Astellas menopause drug
Bio Pharma Dive
MARCH 19, 2024
Following a third successful Phase 3 trial, the company is planning approval filings for the medicine, which it acquired in a $425 million deal four years ago.
Asieris showcases Phase III win in treating precancerous cervical lesions
Pharmaceutical Technology
MARCH 19, 2024
Asieris presented positive Phase III results at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, US.
Elevance to buy Kroger’s specialty pharmacy
Bio Pharma Dive
MARCH 19, 2024
Major pharmacy benefit managers continue to double down on specialty as a reliable source of business amid a growing crop of pharmacy upstarts.
AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal
Pharmaceutical Technology
MARCH 19, 2024
As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.
Riding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in China
Fierce Pharma
MARCH 19, 2024
This year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nat | 2024 marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the Danish drugmaker’s red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nation.
Prevention over cure? Understanding the evolved care continuum and centralised data
Pharmaceutical Technology
MARCH 19, 2024
Preventative care is a shift away from a reactive approach that primarily focuses on treating diseases and managing symptoms after they have manifested.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Do better: The message to the industry from an analysis of clinical evidence submitted to NICE over 20 years
pharmaphorum
MARCH 19, 2024
Do better: The message to the industry from an analysis of clinical evidence submitted to NICE over 20 years Mike.
Eli Lilly’s partnership with Amazon to boost presence in diabetes and obesity markets
Pharmaceutical Technology
MARCH 19, 2024
Eli Lilly's LillyDirect allows for online consultations and prescriptions, and Amazon delivers medicines to the patient’s home.
Improving patient engagement and drug development through AI and enhanced medical affairs roles
pharmaphorum
MARCH 19, 2024
Learn how AI and enhanced medical affairs roles are transforming the landscape of drug development and patient engagement in the health industry. Explore the benefits and advancements in this exciting field.
Microsoft and NVIDIA expand collaboration in healthcare innovation
Pharmaceutical Technology
MARCH 19, 2024
Microsoft has announced plans to broaden its partnership with NVIDIA to leverage gen AI to enhance healthcare and life sciences innovation.
Does Biopharma Drug Discovery Need to Evolve to Include Objective, Longitudinal, Broad-Spectrum Real-World Data?
XTalks
MARCH 19, 2024
It is well established that drugs for psychiatric conditions suffer some of the lowest approval rates when compared to other major therapeutic areas. There are many underlying factors, including complex and poorly understood etiology which are heterogeneous in presentation and presumably underlying pathophysiology. Additionally, traditional clinical studies fail to objectively assess cognitive function as part of patient eligibility criteria or stratify patients according to the presence or degr
China NMPA approves KeChow’s tunlametinib for melanoma
Pharmaceutical Technology
MARCH 19, 2024
The China NMPA has granted approval to KeChow Pharma's tunlametinib for treating patients with NRAS-mutated advanced melanoma.
Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M, his largest compensation package in years
Fierce Pharma
MARCH 19, 2024
After a year marked by Gilead's oncology push and an ongoing focus on CAR-T therapies, CEO Daniel O’Day collected his largest total compensation package since the year he arrived at the Califo | The CEO collected his highest total compensation package since his first year in the role in 2019.
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
Pharmaceutical Technology
MARCH 19, 2024
Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics for an equity value totalling $14bn.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
In his final full year as AbbVie's CEO, Richard Gonzalez collects $25.7M in total pay
Fierce Pharma
MARCH 19, 2024
Guiding AbbVie through an extraordinary decade-plus, riding the success of juggernaut inflammatory disease drug Humira and softening the landing upon its decline, Richard Gonzalez continues to reap | In his final full year as AbbVie’s CEO, Richard Gonzalez pulled down a compensation package worth $25.7 million, according to the company’s proxy filing.
The unmentionables: Challenging inequalities in women’s health
pharmaphorum
MARCH 19, 2024
As Women’s History Month continues, pharmaphorum web editor Nicole Raleigh welcomed a group of expert individuals onto the podcast to discuss not just the inequalities in women’s health, but female leaders within life sciences, too.
WuXi AppTec still sees sales growing and expansions rolling in 2024 despite concerns over US biosecurity bill
Fierce Pharma
MARCH 19, 2024
In moments of great uncertainty, sometimes the best approach is to just press on. | CDMO WuXi AppTec reported solid performance in 2023 and expects good things for the coming year, too. Still, the Chinese contract manufacturer finds itself embroiled in a national security crackdown in the U.S., where a proposed law threatens to upend WuXi's business.
Managing the challenges and embracing the opportunities of EU-wide HTA
pharmaphorum
MARCH 19, 2024
Discover the key strategies for managing the challenges and embracing the opportunities of EU-wide Health Technology Assessment (HTA) in partnership with the European Medicines Agency (EMA) and prospective market authorisation holders (pMAHs).
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Edible Food Packaging: A Sustainable Solution to Plastic Waste
XTalks
MARCH 19, 2024
In recent years, the food industry has faced growing scrutiny over its environmental impact, particularly concerning the use of plastic packaging. This scrutiny has sparked significant interest and investment in alternative packaging solutions, with edible food packaging emerging as a particularly innovative and sustainable option. Let’s explore the rise of edible food packaging and delve into the technologies and types of edible packaging available.
AZ agrees $2bn deal to buy radiopharma firm Fusion
pharmaphorum
MARCH 19, 2024
AstraZeneca upgrades its radiopharma alliance with Fusion Pharma, opting to buy the biotech outright in a deal worth around $2 billion
Orchard Sets $4.25M US Price for Gene Therapy Lenmeldy on Heels of Approval
BioSpace
MARCH 19, 2024
Two days after winning FDA approval, Orchard Therapeutics on Wednesday provided its U.S. launch plans for metachromatic leukodystrophy gene therapy Lenmeldy, which has a wholesale acquisition cost of $4.25 million for the one-time treatment.
Bayer cues up filings for rival to Astellas’ menopause drug
pharmaphorum
MARCH 19, 2024
New phase 3 data sets up filings for Bayer's non-hormonal menopause symptom treatment elinzanetant and a challenge to Astellas’ first-to-market Veozah
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content